Open AccessP587: COVALENT‐101: A PHASE 1 STUDY OF BMF‐219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B‐CELL LYMPHOMA, AND MULTIPLE MYELOMA
Author(s) -
RavandiKashani F.,
Kishtagari A.,
Carraway H.,
Schiller G.,
Curran E.,
Yadav B.,
Cacovean A.,
Morris S.,
Butler T.,
Lancet J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845236.32931.83
Subject(s) - tolerability , medicine , cancer research , multiple myeloma , myeloid leukemia , leukemia , lymphoma , oncology , cancer , adverse effect